NRx Pharmaceuticals, Inc.
NRXP
$2.24
-$0.0501-2.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.78% | -3.33% | 4.45% | -26.53% | -65.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.52% | -47.97% | -11.19% | -36.43% | -55.44% |
| Operating Income | 17.52% | 47.97% | 11.19% | 36.43% | 55.44% |
| Income Before Tax | -109.56% | 73.23% | 9.41% | 40.86% | 57.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.56% | 73.23% | 9.41% | 40.86% | 57.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.56% | 73.23% | 9.41% | 40.86% | 57.70% |
| EBIT | 17.52% | 47.97% | 11.19% | 36.43% | 55.44% |
| EBITDA | 17.53% | 47.98% | 11.19% | 36.43% | 55.45% |
| EPS Basic | -37.76% | 80.01% | 36.93% | 55.60% | 65.09% |
| Normalized Basic EPS | 1.43% | 61.01% | 29.76% | 49.68% | 62.62% |
| EPS Diluted | -37.76% | 80.01% | 37.95% | 55.60% | 65.09% |
| Normalized Diluted EPS | 1.43% | 61.01% | 29.76% | 49.68% | 62.62% |
| Average Basic Shares Outstanding | 51.80% | 33.91% | 43.64% | 33.17% | 21.42% |
| Average Diluted Shares Outstanding | 51.80% | 33.91% | 43.64% | 33.17% | 21.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |